CytoDel Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $295K

  • Investors
  • 4

CytoDel General Information

Description

Operator of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin (BoNT). The company's platform manipulates the BoNT molecule into a drug delivery vehicle that can deliver therapeutic molecules to the inside of neurons with important implications, enabling medical researchers to develop drugs and facilitate the treatment of nervous system disorders, chronic pain, and neurodegenerative diseases.

Contact Information

Website
www.cytodel.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 423 West 127th Street
  • New York, NY 10027
  • United States
+1 (501) 000-0000

CytoDel Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CytoDel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 01-Jan-2023 $295K 00.00 Completed Pre-Clinical Trials
6. Grant 01-Mar-2022 00000 00.00 Completed Pre-Clinical Trials
5. Accelerator/Incubator 00.00 Completed Pre-Clinical Trials
4. Later Stage VC (Series A) 16-Jan-2018 00.00 00.00 000.00 Completed Pre-Clinical Trials
3. Grant 01-Jul-2017 000.00 Completed Pre-Clinical Trials
2. Grant 01-Jan-2014 $224K Completed Pre-Clinical Trials
1. Accelerator/Incubator 13-Dec-2013 Completed Pre-Clinical Trials
To view CytoDel’s complete valuation and funding history, request access »

CytoDel Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1 0,000,000 00.000000 00.00 00.00 00 00.00 00.00
Series A-2 000,000 00.000000 00.00 00.00 00 00.00 00
To view CytoDel’s complete cap table history, request access »

CytoDel Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin (BoNT). The com
Drug Discovery
New York, NY
5 As of 2024
00.00
0000000000 00.00

00000

um dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt
0000000000000
Thousand Oaks, CA
00000 As of 0000
000.00
000000000 - 000.00

000000

isi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit i
0000000000000
Cambridge, MA
0000 As of 0000
000
0000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CytoDel Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 000.00 000000000 - 000.00
Biogen Formerly VC-backed Cambridge, MA 0000 000 000000&0
AbbVie Corporation North Chicago, IL 00000 00.000 000000000 - 00.000
Eli Lilly and Company Corporation Indianapolis, IN 00000 000.00 000000000 00 000.00
Merz Pharma Corporation Frankfurt, Germany 0000
You’re viewing 5 of 5 competitors. Get the full list »

CytoDel Patents

CytoDel Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220333091-A1 Recombinant botulinum neurotoxin with improved safety margin and reduced immunogenicity Pending 30-Sep-2019 00000000

CytoDel Executive Team (3)

Name Title Board Seat
Philip Band Ph.D Co-Founder, Chief Executive Officer & Board Member
Konstantin Ichtchenko Ph.D Co-Founder, CSO and Founding Scientist
You’re viewing 2 of 3 executive team members. Get the full list »

CytoDel Board Members (6)

Name Representing Role Since
André Gudger Self Board Member 000 0000
Dennis Huang Self Board Member 000 0000
Lawrence Remmel JD Self Board Member 000 0000
Margery Fischbein Self Board Member 000 0000
Philip Band Ph.D CytoDel Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

CytoDel Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CytoDel Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Kairos Ventures Venture Capital Minority 000 0000 000000 0
NYU Entrepreneurial Institute Accelerator/Incubator Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view CytoDel’s complete investors history, request access »

CytoDel FAQs

  • When was CytoDel founded?

    CytoDel was founded in 2012.

  • Who is the founder of CytoDel?

    Philip Band Ph.D, Edwin Vazquez Cintron Ph.D, and Konstantin Ichtchenko Ph.D are the founders of CytoDel.

  • Who is the CEO of CytoDel?

    Philip Band Ph.D is the CEO of CytoDel.

  • Where is CytoDel headquartered?

    CytoDel is headquartered in New York, NY.

  • What is the size of CytoDel?

    CytoDel has 5 total employees.

  • What industry is CytoDel in?

    CytoDel’s primary industry is Drug Discovery.

  • Is CytoDel a private or public company?

    CytoDel is a Private company.

  • What is CytoDel’s current revenue?

    The current revenue for CytoDel is 00000.

  • How much funding has CytoDel raised over time?

    CytoDel has raised $3.9M.

  • Who are CytoDel’s investors?

    Kairos Ventures, NYU Entrepreneurial Institute, National Institutes of Health, and U.S. Department of Health and Human Services have invested in CytoDel.

  • Who are CytoDel’s competitors?

    Amgen, Biogen, AbbVie, Eli Lilly and Company, and Merz Pharma are competitors of CytoDel.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »